Mostafa Analoui

Mostafa Analoui, Ph.D., is Head of Healthcare and Life Sciences at The Livingston Group (New York, NY) and Chairman and CEO of Cense Biosciences, Inc. Previously he was the Senior Director at Pfizer Global Research and Development. He is also adjunct Professor of Oral Pathology, Medicine and Radiology at Indiana University. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.

In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He is senior member of IEEE, SPIE, and RSNA. He currently serves as board member of VirtualScopics (Nasdaq: VSCP), Calando Pharmaceutical (Nasdaq: ARWR), BEACON (Biomedical Engineering Alliance and Consortium) and NanoBusiness Alliance. Dr. Analoui’s registrations include Series 7 and 63 with Livingston Securities LLC, a subsidiary of The Livingston Group.